Descripción de la empresa
Aditxt, Inc. operates as a commercial-stage biotechnology entity focused on the discovery and development of products across key areas including immune health, precision health, population health, women's health, and neurologic health. The company utilizes its proprietary AditxtScore technology to empower individuals to understand, manage, and monitor their immune profiles effectively. This enterprise functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself at the intersection of advanced diagnostics and consumer health monitoring solutions. The current market capitalization stands at $269,026, while the annual revenue generated over the trailing twelve months is reported at $3,195, with employee count data not publicly disclosed. These valuation and revenue figures suggest that the company exists as a micro-cap entity with a very limited revenue base relative to its market valuation, indicating a high degree of speculative positioning rather than established commercial scale. The disparity between the reported market cap and the minimal revenue stream highlights the significant reliance on future product development milestones to justify the existing equity value.
Salud financiera
The financial statements reveal a trailing twelve-month revenue of $3,195 contrasted against a substantial net income loss of $-43,101,452, alongside an EBITDA of $-19,298,120. The profound divergence between the negligible revenue and the massive net income deficit indicates an extremely aggressive cost structure where operational expenses vastly exceed all income generated. Free cash flow for the period is reported at $-18,581,398, which signifies that the company is currently burning cash at a rapid pace with no internal financial flexibility to fund operations without external capital injections. Profitability metrics are severely constrained, with a gross margin of 8.4%, an operating margin of -1098725.6%, and a profit margin of 0.0%, illustrating that the company is unable to generate positive returns from its core activities. Liquidity and leverage analysis shows the company holds $3.20M in cash against $3.01M in debt, resulting in a debt-to-equity ratio of 76.04 which reflects a highly leveraged balance sheet relative to its equity base. Short-term liquidity is critically strained as evidenced by a current ratio of 0.31, indicating that current assets are insufficient to cover current liabilities without refinancing or additional financing. Return on Equity stands at -699.1% and Return on Assets is -50.3%, metrics that collectively reveal that management is currently unable to generate value for shareholders or utilize assets effectively to produce earnings.
Evaluación de valoración
Valuation multiples for Aditxt, Inc. present a challenging picture, with a trailing P/E ratio listed as N/A due to negative earnings and a forward P/E of -0.05. The price-to-book ratio is recorded at -0.00, which implies that the market valuation is detached from the company's tangible book value, often seen in early-stage biotechnology firms with significant intangible assets or development costs. Alternative valuation metrics such as the price-to-sales ratio of 84.20 and an EV/EBITDA of 0.07 suggest that investors are pricing the stock based on potential future breakthroughs rather than current financial performance. The stock has exhibited extreme volatility, with a 52-week high of $3426.16 and a 52-week low of $0.50, meaning the current price sits at a level significantly below the historical peak and well above the absolute floor. The beta value is not available for calculation, preventing a direct assessment of price volatility relative to the broader market index. The massive gap between the 52-week high and the current market price underscores the speculative nature of the investment and the potential for significant price correction if development timelines are delayed. The negative forward P/E further reinforces that the market does not anticipate normalized earnings in the near term, consistent with the company's current financial trajectory.
Growth & Income
Revenue growth year-over-year is reported at -86.6%, while earnings growth year-over-year is listed as N/A due to the lack of positive earnings to measure against prior periods. The negative revenue growth rate indicates a contraction in sales or a shift in the business model, while the absence of earnings growth data implies that profitability has not been achieved to support a meaningful growth comparison. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means all available capital is theoretically available for reinvestment into research and development rather than distribution to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of income generation, reflecting the high-risk nature of commercial-stage biotechnology companies that have not yet reached commercial viability. This financial structure requires continuous external funding to sustain operations and advance product pipelines, creating a dependency on capital markets that poses inherent risks to the company's continuity. The lack of dividend income and negative growth metrics aligns with the typical lifecycle of a biotechnology firm still navigating the path from discovery to market penetration.